New dye combo could spare ovarian cancer patients unnecessary surgery
NCT ID NCT05937620
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether a combination of two dyes (technetium-99m albumin nanocolloid and indocyanine green) can accurately identify the first lymph node where ovarian cancer might spread. The goal is to improve surgical staging and potentially avoid removing many lymph nodes. The study will enroll 62 women with early-stage epithelial ovarian cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Technetium-99m albumin nanocolloid and indocyanine green (ICG)
- What this could lead to
- If successful, this could lead to a more precise and less invasive way to stage early ovarian cancer, potentially reducing the need for extensive lymph node removal.
- What could go wrong
- This is a small pilot study (62 participants) focused on diagnostic accuracy, not treatment. The tracers may not detect all affected nodes, and results may not apply to later-stage cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN EPITHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laura Burunat
RECRUITINGBarcelona, Catalonia, 08036, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.